Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.

ABSTRACT:

Background and aims

No effective pharmacotherapy for methamphetamine (MA) use disorder has yet been found. This study evaluated sustained-release methylphenidate (MPH-SR) compared with placebo (PLA) for treatment of MA use disorder in people also undergoing behavioral support and motivational incentives.

Design

This was a randomized, double-blind, placebo-controlled design with MPH-SR or PLA provided for 10 weeks (active phase) followed by 4 weeks of single-blind PLA. Twice-weekly clinic visits, weekly group counseling (CBT) and motivational incentives (MI) for MA-negative urine drug screens (UDS) were included.

Setting

Treatment sites were in Los Angeles, California (LA) and Honolulu, Hawaii (HH), USA.

Participants

A total of 110 MA-dependent (via DSM-IV) part

SUBMITTER: Ling W 

PROVIDER: S-EPMC4127124 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature